Joseph W Harding

US Patent:

7118747, Oct 10, 2006

Filed:

Sep 30, 2003

Appl. No.:

10/675470

Inventors:

Joseph W Harding - Pullman WA, US
John W Wright - Pullman WA, US

Assignee:

Pacific Northwest Biotechnology Inc. - Pullman WA
Washington State University Research Foundation - Pullman WA

International Classification:

A61K 39/00
A61K 38/00

US Classification:

4241841, 4241851, 530316

Abstract:

ATreceptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. ATreceptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that is characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells.

US Patent:

7910555, Mar 22, 2011

Filed:

Jul 6, 2007

Appl. No.:

11/774517

Inventors:

Joseph W. Harding - Pullman WA, US
John W. Wright - Pullman WA, US
Patrick D. Elias - Pullman WA, US
Brent J. Yamamoto - Pullman WA, US

Assignee:

Washington State University Research Foundation - Pullman WA

International Classification:

A61K 38/08

US Classification:

514 217

Abstract:

The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis cancer metastasis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, including altering hepatocyte growth factor activity or c-Met receptor activity by administering an angiotensin-like factor that specifically binds to a cell surface c-Met receptor.

US Patent:

8236761, Aug 7, 2012

Filed:

Jan 10, 2008

Appl. No.:

11/972487

Inventors:

Joseph W. Harding - Pullman WA, US
John W. Wright - Pullman WA, US
Patrick D. Elias - Pullman WA, US
Brent J. Yamamoto - Pullman WA, US

Assignee:

Washington State University Research Foundation - Pullman WA

International Classification:

A61K 38/18
A61K 38/08
A61K 38/10

US Classification:

514 95, 514 214, 514 216, 514 217, 514 218

Abstract:

The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis, cancer metastasis, adipogenesis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, including cancer, obesity and conditions associated with obesity, and other disorders, for example, by altering hepatocyte growth factor activity or c-Met receptor activity by administering an angiotensin-like factor that specifically binds to a cell surface c-Met receptor.

US Patent:

20060128630, Jun 15, 2006

Filed:

Nov 16, 2005

Appl. No.:

11/280954

Inventors:

Joseph Harding - Pullman WA, US
John Wright - Pullman WA, US

Assignee:

Pacific Northwest Biotechnology Inc. - Pullman WA
Washington State University Research Foundation - Pullman WA

International Classification:

A61K 38/08

US Classification:

514016000

Abstract:

ATreceptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. ATreceptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that is characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells.

US Patent:

20080194490, Aug 14, 2008

Filed:

Oct 30, 2007

Appl. No.:

11/929205

Inventors:

Joseph W. Harding - Pullman WA, US
John W. Wright - Pullman WA, US

International Classification:

A61K 38/08
C07K 7/06
A61P 35/00

US Classification:

514 17, 514 18, 530330, 530329

Abstract:

ATreceptor agonists are potent activators of angiogenesis and can be used to treat diseases that are characterized by vascular insufficiency. ATreceptor antagonists, which are potent inhibitors of angiogenesis, and can be used as anti-angiogenic agents for the treatment of cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerotic plaque formation, and any disease process that is characterized by excessive, undesired or inappropriate angiogenesis or proliferation of endothelial cells.

US Patent:

20130023475, Jan 24, 2013

Filed:

Jul 12, 2012

Appl. No.:

13/547601

Inventors:

Joseph W. Harding - Pullman WA, US
John W. Wright - Pullman WA, US
Patrick D. Elias - Pullman WA, US
Brent J. Yamamoto - Pullman WA, US
Leen H. Kawas - Pullman WA, US

International Classification:

A61K 38/08
A61K 38/10
A61P 25/16
A61P 25/00

US Classification:

514 95, 514 177, 514 179

Abstract:

The cell surface c-Met receptor, through which hepatocyte growth factor (HGF) signals are mediated, has now been identified as the Angiotensin-IV receptor (AT(4)R) in processes that include HGF-regulated cell motility, angiogenesis, cancer metastasis, adipogenesis and others. Disclosed are angiotensin-like factor compositions and methods for using them to diagnose, prevent and/or treat conditions associated with c-Met dysregulation, including cancer, obesity and conditions associated with obesity, and other disorders, for example, by altering hepatocyte growth factor activity or c-Met receptor activity by administering an angiotensin-like factor that specifically binds to a cell surface c-Met receptor. In addition, members of this group of molecules may useful for treating or preventing the development of neurodegenerative diseases like general dementia, Alzheimer's disease, Parkinson's disease, and Amyotrophic Lateral Sclerosis and initiating recovery from traumatic brain injury and spinal cord trauma. These peptides and peptidomimetics may be therapeutically useful whenever increased neurotrophic activity would be clinically advantageous.

US Patent:

58543880, Dec 29, 1998

Filed:

Dec 22, 1994

Appl. No.:

8/360784

Inventors:

Joseph W. Harding - Pullman WA
John W. Wright - Pullman WA

Assignee:

Washington State University Research Foundation - Pullman WA

International Classification:

A61K 3804
A61K 3906
C07K 1600
C07K 500

US Classification:

530329

Abstract:

A unique and novel angiotensin AT4 receptor and AIV ligand system for binding a small N-terminal hexapeptide fragment of Angiotensin II (referred to as AIV, with amino acid sequence Val. sub. 1 -Tyr. sub. 2 -Ile. sub. 3 -His. sub. 4 -Pro. sub. 5 -Phe. sub. 6 ; SEQ. ID. NO. 1) is disclosed. AIV ligand binds saturably, reversibly, specifically, and with high affinity to membrane AT4 receptors in a variety of tissues, including heart, lung, kidney, aorta, brain, liver, and uterus, from many animal species. The AT4 receptor is pharmacologically distinct from classic angiotensin receptors (AT1 or AT2). The system employs AIV or C-terminally truncated or extended AIV-like peptides (e. g. , VYIHPFX; SEQ. ID. NO. 8) as the signaling agent, and the AT4 plasma membrane receptor as the detection mechanism.

US Patent:

6022696, Feb 8, 2000

Filed:

Apr 2, 1998

Appl. No.:

9/054308

Inventors:

Joseph W. Harding - Pullman WA
John W. Wright - Pullman WA

Assignee:

Washington State University Research Foundation - Pullman WA

International Classification:

G01N 33567
C07K 714

US Classification:

435 721

Abstract:

A unique and novel angiotensin AT4 receptor and AIV ligand system for binding a small N-terminal hexapeptide fragment of Angiotensin II (referred to as AIV, with amino acid sequence Val. sub. 1 -Tyr. sub. 2 -Ile. sub. 3 -His. sub. 4 -Pro. sub. 5 -Phe. sub. 6 ; SEQ. ID. NO. 1) is disclosed. AIV ligand binds saturably, reversibly, specifically, and with high affinity to membrane AT4 receptors in a variety of tissues, including heart, lung, kidney, aorta, brain, liver, and uterus, from many animal species. The AT4 receptor is pharmacologically distinct from classic angiotensin receptors (AT1 or AT2). The system employs AIV or C-terminally truncated or extended AIV-like peptides (e. g. , VYIHPFX; SEQ. ID. NO. 8) as the signaling agent, and the AT4 plasma membrane receptor as the detection mechanism.